Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS1819-SD Combination Therapy in CF Patients with Severe EPI
NCT04302662Phase 2Completed
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of adrulipase alfa in exocrine pancreatic insufficiency (EPI), sponsored by Entero Therapeutics, Inc. Primary endpoints: Coefficient of fat absorption at 15 days and Adverse Events at 81 days. Started Jun 2019; status: completed.
02
Drugs
adrulipase alfa
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT04302662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302662.